

Spotlight on Uterine Cancer

An estimated 69,120 new cases of uterine cancer were diagnosed in the U.S. in 2025.

Unfortunately, age-adjusted death rates have been rising on average 1.6% each year from 2014-2023, showing the need for more research. Currently, the five-year relative survival rate is 81%.

Most cases of endometrial cancer are diagnosed in postmenopausal women aged 45-74.



Our Impact on Uterine Cancer Research

We've funded

13 grants totaling \$4.8 million.

V Foundation funded researchers, over their careers, have:

Received

46 grants and over \$82 million in funding.

Produced

over 1,000 publications.

Worked on

32 clinical trials.

V Foundation Funded Researchers – Proven Positive Impact

- **Jamie Bakkum-Gamez, M.D.**, a 2016 Translational Grant awardee from Mayo Clinic-Rochester, has focused her research on developing the first-ever screening test for uterine cancer.
- Early-stage endometrial cancers have an excellent prognosis, but 10-15% of newly diagnosed endometrial cancers can be aggressive and highly lethal. Early detection approaches are not well-established, but they have the potential to be game-changing and save lives.
- Dr. Bakkum-Gamez is identifying DNA modifications seen in uterine cancer and researched if there were markers present in vaginal fluid from tampons that distinguished normal endometrium from endometrial cancer.
- While larger studies need to be done to validate these findings, the data are an extremely important step forward in developing accurate, non-invasive screening tests for uterine cancer.



*Jamie Bakkum-Gamez, M.D.,
2016 Translational Grantee*